X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.gilead.com/news-and-press/press-room/press-releases/2024/4/gilead-sciences-announces-first-quarter-2024-financial-results
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217037
https://www.fiercepharma.com/marketing/dovato-advert-dispute-between-viiv-and-gilead-escalates-feds-after-self-regulatory
https://www.pharmaceutical-technology.com/news/gilead-ec-hiv-treatment/
https://www.fool.com/investing/2022/09/14/my-biggest-worry-about-gilead-sciences/
https://www.fiercepharma.com/pharma/gilead-pads-case-top-seller-biktarvy-hivhepatitis-b-coinfection
https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-bictegravir-sodium-emtricitabine-tenofovir-alafenamide-fumarate-tablet-1649312230.pdf
https://www.pharmaceutical-technology.com/news/fda-gilead-biktarvy-paediatric-hiv/
http://www.pharmatimes.com/news/gileads_hiv_therapy_biktarvy_demonstrates_long-term_sustained_efficacy_1364766
https://www.biospectrumasia.com/news/100/16945/gileads-biktarvy-sustains-viral-suppression-and-tolerability-in-asian-hiv-patients.html
https://www.biospace.com/article/releases/gilead-presents-biktarvy-findings-from-switch-studies-and-amp-analysis-of-real-world-bicstar-study-at-hiv-glasgow-2020-/
https://www.biospace.com/article/releases/gilead-presents-biktarvy-findings-from-switch-studies-and-amp-analysis-of-real-world-bicstar-study-at-hiv-glasgow-2020-/
https://www.fiercepharma.com/marketing/gilead-slammed-for-misleading-claim-biktarvy-against-gsk-s-rival-hiv-drug
https://www.raps.org/news-and-articles/news-articles/2019/11/us-sues-gilead-over-hiv-drug-patents
https://www.fiercepharma.com/pharma/gilead-riding-biktarvy-success-as-hiv-portfolio-overall-revenue-shows-signs-decline
https://www.biospectrumasia.com/news/48/14247/china-nmpa-approves-biktarvy-to-treat-hiv-1-infection.html
https://www.raps.org/news-and-articles/news-articles/2019/8/asia-regulatory-roundup-china-approves-gilead-hiv
https://www.businesswire.com/news/home/20190809005217/en/China-National-Medical-Products-Administration-Approves-Biktarvy%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.fiercepharma.com/marketing/gildead-biktarvy-jumps-to-no-2-pharma-tv-ad-spending-for-june-pfizer-xeljanz-drops-off
https://www.fiercepharma.com/pharma/move-aside-humira-merck-s-keytruda-will-capture-industry-s-top-sales-ranking-2024-report
https://www.fiercepharma.com/marketing/j-j-sponsored-film-about-first-aids-ward-san-francisco-picked-up-for-broader-distribution
https://www.cnbc.com/2019/05/02/reuters-america-update-1-gilead-to-separate-kite-cell-therapy-unit-posts-higher-profit.html
https://en.prnasia.com/releases/apac/singapore-health-sciences-authority-approves-biktarvy-r-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv-1-infection-237107.shtml
https://www.fiercepharma.com/pharma/as-advair-generic-hits-gsk-looks-to-oncology-as-new-growth-point-alongside-shingrix-and-hiv
https://www.statnews.com/2019/01/02/cheat-sheet-biotechs-2019/
https://www.businesswire.com/news/home/20181030005503/en/Gilead-Announces-96-Week-Results-Phase-3-Study
https://www.fiercepharma.com/pharma/gilead-beats-q3-forecasts-as-hiv-portfolio-soars-but-it-enough-to-combat-falling-hcv-sales
http://www.pharmatimes.com/news/gilead_raises_outlook_despite_dip_in_revenue_1257213
http://www.pharmatimes.com/news/four_new_medicines_available_via_nhs_scotland_1251812
https://www.fiercepharma.com/pharma/gilead-s-top-execs-milligan-and-martin-stepping-down
https://endpts.com/jj-joins-blockbuster-hiv-combo-race-with-newly-approved-4-in-1-pill/
https://www.biospace.com/article/is-gilead-poised-for-a-comeback-/
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004449/WC500250891.pdf
Market Place
Share 
